SCHEDULE: Biotechnology Value Fund Group Discloses Significant 7.4% Stake in Nektar Therapeutics

A group of investment entities led by Biotechnology Value Fund, L.P. and Mark N. Lampert has disclosed a collective beneficial ownership of 7.4% of Nektar Therapeutics' common stock.

Summary

• Biotechnology Value Fund, L.P. (BVF) beneficially owns 661,758 shares, representing approximately 3.8% of Nektar Therapeutics' outstanding common stock.
• BVF I GP LLC (BVF GP), as the general partner of BVF, may be deemed to beneficially own 661,758 shares, or approximately 3.8%.
• Biotechnology Value Fund II, L.P. (BVF2) beneficially owns 517,813 shares, representing approximately 3.0% of Nektar Therapeutics' outstanding common stock.
• BVF II GP LLC (BVF2 GP), as the general partner of BVF2, may be deemed to beneficially own 517,813 shares, or approximately 3.0%.
• Biotechnology Value Trading Fund OS LP (Trading Fund OS) beneficially owns 71,367 shares, representing approximately 0.4% of Nektar Therapeutics' outstanding common stock.
• BVF Partners OS Ltd. (Partners OS), as the general partner of Trading Fund OS, may be deemed to beneficially own 71,367 shares, or approximately 0.4%.
• BVF GP Holdings LLC (BVF GPH), as the sole member of BVF GP and BVF2 GP, may be deemed to beneficially own 1,179,571 shares, representing approximately 6.8% of Nektar Therapeutics' outstanding common stock.
• BVF Partners L.P. (Partners), as the investment manager, and BVF Inc. (general partner of Partners), along with Mark N. Lampert (director and officer of BVF Inc.), may each be deemed to beneficially own 1,276,595 shares, representing approximately 7.4% of Nektar Therapeutics' outstanding common stock.
• The percentages are based on 17,301,061 shares of Nektar Therapeutics common stock outstanding as of July 2, 2025.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not convey a positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• A significant investment group, led by Mark N. Lampert, has disclosed a substantial beneficial ownership stake of 7.4% in Nektar Therapeutics, indicating a notable investment position.

Negatives

• No specific negative information regarding Nektar Therapeutics' operations or financial performance is disclosed in this ownership filing.

Risks

• No specific risks related to Nektar Therapeutics' business or operations are detailed in this beneficial ownership report.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Nektar Therapeutics' future operations or financial performance.

Industry Context

This filing represents a standard disclosure of a significant passive investment stake by an institutional investor group in a biotechnology company. Such disclosures are common in the biotech sector, where specialized funds often take positions in companies with promising pipelines or strategic value.

Comparison to Industry Standards

• This document is a Schedule 13G filing, which is a regulatory disclosure of beneficial ownership. It does not contain information that allows for a direct comparison of Nektar Therapeutics' operational or financial results to industry benchmarks or specific comparable companies/projects. The filing solely details the ownership structure of a specific investment group in Nektar Therapeutics.

Stakeholder Impact

• Shareholders are impacted by the disclosure of a significant institutional investment group holding a 7.4% stake, which can influence market perception and potentially share price.

Key Dates

Keywords

Nektar Therapeutics, NKTR, Biotechnology Value Fund, Mark N. Lampert, Schedule 13G, beneficial ownership, common stock, investment, SEC filing